Johnson & Johnson is getting ready to share its Q3 earnings, and analysts have changed their predictions.

JNJ · Johnson & Johnson

The AI's read

The expected rise in sales points to more business, but analysts also expect lower profit. Recent positive therapy findings and raised analyst targets are encouraging, yet they do not resolve that split. The story gives no clear reason to change the view of JNJ.